<DOC>
	<DOC>NCT00081315</DOC>
	<brief_summary>The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.</brief_summary>
	<brief_title>Subcutaneous Amifostine (EthyolÂ®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>You may be eligible for this study if you are 18 years of age or older and: Have UnResectable Stage IIIA or IIIB Non Small Cell Lung Cancer Have never had prior chemotherapy with Paclitaxel or Carboplatin Have never had prior thoracic radiation therapy (XRT)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>- Non-Small cell lung cancer</keyword>
</DOC>